Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus
Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus
复制标题
DOI：
10.3109/08916934.2010.545846
复制
发表时间：
2011-08-01
期刊：
影响因子：
3.5
通讯作者：
Takasaki, Yoshinari
中科院分区：
文献类型：
--
作者：
Minowa, Kentaro;Amano, Hirofumi;Takasaki, Yoshinari
目的：系统性红斑狼疮(SLE)以B细胞耐受性丧失和多克隆B细胞活化为特征。Syndecan-1(CD138)表达于B细胞来源的浆细胞，在SLE发病机制中起重要作用。我们检测了活动期SLE患者外周血中可溶性CD138(SCD138)水平和细胞表面CD138的表达水平，并检测了患者血清中增殖诱导配体BAFF(APRIL)和CD138水平之间的相关性。用双抗体夹心法检测血清sCD138、sBAFF、sAPRIL水平，用流式细胞仪检测细胞表面CD138。逆转录-聚合酶链式反应(RT-PCR)检测CD138基因表达水平。结果：活动期SLE患者外周血中CD138、CD138 mRNA水平及CD20(-)、CD38(+)、CD138(+)浆细胞数均高于正常对照组。SLE患者血清sCD138水平与CD20(-)、CD38(+)、CD138(+)浆细胞比例相关。而活动期SLE患者血清sCD138水平降低，且与sAPRIL水平呈负相关。结论：sCD138可作为疾病活动的替代指标，Syndecan-1/APRIL信号通路可能成为SLE患者治疗的潜在靶点。
Objective: Systemic lupus erythematosus (SLE) is characterized by loss of B cell tolerance and by the presence of polyclonal B cell activation. Syndecan-1 (CD138) is expressed on plasma cells derived from B cells, and is suspected to play a role in SLE. We evaluated the level of soluble CD138 (sCD138) and cell surface expression of CD138 in patients with active SLE, and also examined correlations among the serum levels of BAFF, a proliferation-inducing ligand (APRIL), and CD138 in these patients.Methods: Peripheral blood samples were obtained from 22 SLE patients in an active disease state and 14 normal controls. The levels of serum sCD138, sBAFF, and sAPRIL were measured using ELISA, and cell surface CD138 was analyzed by flow cytometry. The levels of CD138 mRNA were analyzed by RT-PCR. Blood samples were obtained longitudinally when the patients were in an inactive disease state.Results: The levels of circulating CD138, CD138 mRNA in PBMC, and the numbers of CD20(-)CD38(+)CD138(+) plasma cells were increased in patients with active SLE in comparison with normal controls. Furthermore, the serum sCD138 level in SLE patients was found to correlate with the proportion of CD20(-)CD38(+)CD138(+) plasma cells. On the other hand, patients with active SLE showed a reduced level of sCD138, and this was inversely correlated with the serum level of sAPRIL.Conclusions: These results suggest that sCD138 may be applicable as a surrogate marker of disease activity, and that syndecan-1/APRIL signaling may be a potential therapeutic target for patients with active SLE.